Alterity Therapeutics filed Form 20-F and XBRL data with SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 3 September 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has announced that

Alterity Therapeutics filed Form

20-F and XBRL data with SEC

MELBOURNE, AUSTRALIA AND SAN FRANCISCO,

USA - 3 September 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company")

has announced that it has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year ended

June 30, 2021 with the US Securities and Exchange Commission (the SEC). The annual report is available on the company website https://alteritytherapeutics.com/.

Shareholders may receive a hard copy of the annual report free of charge upon request.

The Company has also filed the XBRL interactive data with the

SEC, which is available via the company website at https://alteritytherapeutics.com/investor-centre/news/2021/09/03/xbrl-30-june-2021-filed-

Authorization & Additional information

This announcement was authorized by David Stamler, CEO of Alterity

Therapeutics Limited.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage

biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's

lead asset, ATH434, has the potential to treat various forms of Parkinsonian disorders. Alterity also has a broad drug discovery platform

generating patentable chemical to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California,

USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

Authorisation & Additional information

This announcement was authorized by David

Stamler, CEO of Alterity Therapeutics Limited.

Contact: Investor Relations

Forward Looking Statements

This press release contains

"forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities

Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends,"

"hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates,"

and other similar expressions, but these words are not the exclusive means of identifying suchstatements.

factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described

in the sections titled "Risk Factors" in

the Company's filings with the SEC, including

its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements

relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical

trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not

historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties

relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the

Company's drug components, including, but not

limited to, ATH434, uncertainties relating to the impact of the novel coronavirus (COVID-19) pandemic on the company's

business, operations and employees, the ability of the Company to procure additional future sources of financing, unexpected adverse

side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could

slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade

secrets, including, but not limited to, the intellectual property relating to ATH434.

Any forward-looking statement

made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is

made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time

to time, whether as a result of new information, future developments or otherwise.